WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio Inc (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation. “Tevogen Bio’s business combination with Semper Paratus can help us achieve our goal to become the first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, and we
Business Wire Merger/Acquisition News
